Mechanism of Action of Dutasteride
Dutasteride works by competitively and specifically inhibiting both type 1 and type 2 isoforms of the enzyme 5-alpha-reductase, which converts testosterone to dihydrotestosterone (DHT), the primary androgen responsible for prostate growth and development. 1
Enzymatic Inhibition
Dutasteride forms an extremely stable enzyme complex with both 5-alpha-reductase isoforms, with dissociation occurring very slowly under both in vitro and in vivo conditions 1. This dual inhibition distinguishes dutasteride from finasteride, which only blocks the type 2 isoform 2.
Isoform Distribution
- Type 2 isoenzyme: Primarily active in reproductive tissues (prostate)
- Type 1 isoenzyme: Active in skin, liver, and also expressed in prostate tissue 1
Biochemical Effects
DHT Suppression
The drug achieves near-maximal DHT suppression rapidly and consistently:
- 85% reduction in serum DHT after 1 week
- 90% reduction after 2 weeks
- 94-95% reduction maintained long-term (1-4 years) 1
Intraprostatic DHT levels are reduced by 83% at 2 weeks, reaching 90-93% suppression by 1-4 months 3. This greater and more consistent DHT decrease compared to finasteride results from the dual inhibition mechanism 2.
Testosterone Changes
A reciprocal increase in testosterone occurs with DHT suppression:
- Median serum testosterone increases by 19-26% over 1-3 years
- Mean and median levels remain within physiologic range
- Intraprostatic testosterone increases but generally remains lower than baseline intraprostatic DHT levels in untreated patients 1, 3
Clinical Relevance for Prostate Cancer
Important Caveat for Your Patient
Dutasteride does not bind to the human androgen receptor 1. Its anticancer effect is purely through androgen deprivation at the tissue level, not through direct receptor antagonism.
PSA Monitoring Considerations
Critical for cancer surveillance: Dutasteride causes a greater and more consistent PSA suppression than finasteride, but no uniform multiplier has been prospectively validated 2. While finasteride typically requires a 2x multiplier after 12 months, the exact adjustment for dutasteride remains undefined in guidelines. This creates a significant challenge for monitoring your 56-year-old patient with low-risk prostate cancer, as PSA changes may not reliably indicate disease progression or response.
Prostate Volume Effects
In BPH patients treated for 12 weeks, mean prostatic tissue DHT concentrations decreased from 5,793 pg/g (placebo) to 784 pg/g (dutasteride), while testosterone concentrations increased from 93 pg/g to 2,073 pg/g 1.